Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Comparative Efficacy and Safety of Osimertinib Versus First-Generation EGFR-TKIS as First-Line Treatment in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Objective of this study was to compare the efficacy and safety of Osimertinib versus first-generation EGFR-TKIs (gefitinib, erlotinib) as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) through a systematic review and meta-analysis. A systematic review was conducted follow...

Manojkumar Venkatesan, Dhivya Dhanasekaran, D. M et al. · 0 citations
Open access Sep 2026

Model-Informed Population Pharmacokinetic Simulation of Osimertinib and Az5104 in a Virtual Indian Nsclc Cohort: Exposure Variability, QTCF Tail-Risk Quantification, and Risk-Stratified ECG Monitoring

Objective: Osimertinib is a third generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has concentration-dependent QTc prolongation. Pivotal trials are under-representing Indian patients and they could differ in specific baseline characteristics (covariates) that are important for drug...

Manojkumar Venkatesan, Dhivya Dhanasekaran, D. M et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.